Navigation Links
Micromet Receives Regulatory Approval to Conduct a Phase 2 Clinical Trial Investigating MT103 (MEDI-538) in Patients with Acute Lymphoblastic Leukemia
Date:10/18/2007

esults to differ materially from any future results expressed or implied by any forward-looking statements include the risk that product candidates that appeared promising in early research, preclinical studies or clinical trials do not demonstrate safety and/or efficacy in subsequent clinical trials, the risk that encouraging results from early research, preclinical studies or clinical trials may not be confirmed upon further analysis of the detailed results of such research, preclinical study or clinical trial, the risk that additional information relating to the safety, efficacy or tolerability of our product candidates may be discovered upon further analysis of preclinical or clinical trial data, the risk that we or our collaborators will not obtain approval to market our product candidates, the risks associated with reliance on outside financing to meet capital requirements, and the risks associated with reliance on collaborators, including MedImmune, Merck Serono, TRACON and Nycomed, for the funding or conduct of further development and commercialization activities relating to our product candidates. You are urged to consider statements that include the words "ongoing", "may", "will", "would", "could", "should", "believes", "estimates", "projects", "potential", "expects", "suggests", "plans", "anticipates", "intends", "continues", "forecast", "designed", "goal", or the negative of those words or other comparable words to be uncertain and forward-looking. These factors and others are more fully discussed in our periodic reports and other filings with the SEC.


'/>"/>
SOURCE Micromet, Inc.
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine news :

1. Infant receives first bloodless liver transplant
2. British MPs Say Prostate Cancer Receives Low Priority in the NHS
3. Fifth US Patient Receives Artificial Heart
4. Northfield Labs Receives FDA Comments
5. Abbott Receives CE Mark Certification
6. Zactima Receives Fast Track Designation By The FDA
7. East London Receives World Class New Private Hospital Facility
8. Brinda Karat Receives Legal Notice over Ramdev Issue
9. Quake-Hit Pakistan Receives 30 Field Hospitals From Cuba
10. Medtronic’s Insulin Pump Receives Regulatory Approva
11. Aurobindo Receives Approval from USFDA for anti-AIDS drug

Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/10/2009)...AFFHAUSEN, Switzerland, Nov. 10 /PRNewswire-FirstC...nts) , , Q4 2009 Q4 2008 ... ------- ------- -------- ------- ----...284 (16)% $17,237 $20,199 (15)%, Inco... $207 $264 (22)% ($1,833) $1,095...
(Date:11/10/2009)... ANGELES, Nov. 10 Research conduct... Inc. (CARD), shines new light on the effects of a...treatment for children with autism and related dis... Therapy for Children with Autism" study reveals t...3 atmospheres of pressure, does not have a signifi...
(Date:11/10/2009)...he science is in place. Why are so many suffering?...swire/ -- Pain medicine physicians from the Americ...vance the call for better pain care as they joined... a closed-door National Pain Summit that took plac... Texas. ,, AAPM leaders have been vigilant in...
(Date:11/10/2009)...VARD, N.C., Nov. 10 Gaia Herbs, a ...anic herbal products, announces Quick Defense Liqu...ic Echinacea, organic Elderberry, organic Ginger a...ne system at onset. Working synergistically, the b... used for short periods of time during sinus and r...
(Date:11/10/2009)... The "Think Outside the Box&q...in health reform is to have policyholders select a...on or a plan which does not. , ...Saturday’s near-derailment of comprehensive ...bility that the same thing could happen again in t...
Breaking Medicine News(10 mins):Health News:Tyco International Reports Fourth Quarter Earnings From Continuing Operations Before Special Items of $0.61 Per Share and GAAP Earnings of $0.44 Per Share 2Health News:Tyco International Reports Fourth Quarter Earnings From Continuing Operations Before Special Items of $0.61 Per Share and GAAP Earnings of $0.44 Per Share 3Health News:Tyco International Reports Fourth Quarter Earnings From Continuing Operations Before Special Items of $0.61 Per Share and GAAP Earnings of $0.44 Per Share 4Health News:Tyco International Reports Fourth Quarter Earnings From Continuing Operations Before Special Items of $0.61 Per Share and GAAP Earnings of $0.44 Per Share 5Health News:Tyco International Reports Fourth Quarter Earnings From Continuing Operations Before Special Items of $0.61 Per Share and GAAP Earnings of $0.44 Per Share 6Health News:Tyco International Reports Fourth Quarter Earnings From Continuing Operations Before Special Items of $0.61 Per Share and GAAP Earnings of $0.44 Per Share 7Health News:Tyco International Reports Fourth Quarter Earnings From Continuing Operations Before Special Items of $0.61 Per Share and GAAP Earnings of $0.44 Per Share 8Health News:Tyco International Reports Fourth Quarter Earnings From Continuing Operations Before Special Items of $0.61 Per Share and GAAP Earnings of $0.44 Per Share 9Health News:Tyco International Reports Fourth Quarter Earnings From Continuing Operations Before Special Items of $0.61 Per Share and GAAP Earnings of $0.44 Per Share 10Health News:Tyco International Reports Fourth Quarter Earnings From Continuing Operations Before Special Items of $0.61 Per Share and GAAP Earnings of $0.44 Per Share 11Health News:Tyco International Reports Fourth Quarter Earnings From Continuing Operations Before Special Items of $0.61 Per Share and GAAP Earnings of $0.44 Per Share 12Health News:Tyco International Reports Fourth Quarter Earnings From Continuing Operations Before Special Items of $0.61 Per Share and GAAP Earnings of $0.44 Per Share 13Health News:Tyco International Reports Fourth Quarter Earnings From Continuing Operations Before Special Items of $0.61 Per Share and GAAP Earnings of $0.44 Per Share 14Health News:Tyco International Reports Fourth Quarter Earnings From Continuing Operations Before Special Items of $0.61 Per Share and GAAP Earnings of $0.44 Per Share 15Health News:Tyco International Reports Fourth Quarter Earnings From Continuing Operations Before Special Items of $0.61 Per Share and GAAP Earnings of $0.44 Per Share 16Health News:Tyco International Reports Fourth Quarter Earnings From Continuing Operations Before Special Items of $0.61 Per Share and GAAP Earnings of $0.44 Per Share 17Health News:Tyco International Reports Fourth Quarter Earnings From Continuing Operations Before Special Items of $0.61 Per Share and GAAP Earnings of $0.44 Per Share 18Health News:Tyco International Reports Fourth Quarter Earnings From Continuing Operations Before Special Items of $0.61 Per Share and GAAP Earnings of $0.44 Per Share 19Health News:Tyco International Reports Fourth Quarter Earnings From Continuing Operations Before Special Items of $0.61 Per Share and GAAP Earnings of $0.44 Per Share 20Health News:Tyco International Reports Fourth Quarter Earnings From Continuing Operations Before Special Items of $0.61 Per Share and GAAP Earnings of $0.44 Per Share 21Health News:Tyco International Reports Fourth Quarter Earnings From Continuing Operations Before Special Items of $0.61 Per Share and GAAP Earnings of $0.44 Per Share 22Health News:Tyco International Reports Fourth Quarter Earnings From Continuing Operations Before Special Items of $0.61 Per Share and GAAP Earnings of $0.44 Per Share 23Health News:Tyco International Reports Fourth Quarter Earnings From Continuing Operations Before Special Items of $0.61 Per Share and GAAP Earnings of $0.44 Per Share 24Health News:Tyco International Reports Fourth Quarter Earnings From Continuing Operations Before Special Items of $0.61 Per Share and GAAP Earnings of $0.44 Per Share 25Health News:Tyco International Reports Fourth Quarter Earnings From Continuing Operations Before Special Items of $0.61 Per Share and GAAP Earnings of $0.44 Per Share 26Health News:Tyco International Reports Fourth Quarter Earnings From Continuing Operations Before Special Items of $0.61 Per Share and GAAP Earnings of $0.44 Per Share 27Health News:Tyco International Reports Fourth Quarter Earnings From Continuing Operations Before Special Items of $0.61 Per Share and GAAP Earnings of $0.44 Per Share 28Health News:Tyco International Reports Fourth Quarter Earnings From Continuing Operations Before Special Items of $0.61 Per Share and GAAP Earnings of $0.44 Per Share 29Health News:Tyco International Reports Fourth Quarter Earnings From Continuing Operations Before Special Items of $0.61 Per Share and GAAP Earnings of $0.44 Per Share 30Health News:Tyco International Reports Fourth Quarter Earnings From Continuing Operations Before Special Items of $0.61 Per Share and GAAP Earnings of $0.44 Per Share 31Health News:Tyco International Reports Fourth Quarter Earnings From Continuing Operations Before Special Items of $0.61 Per Share and GAAP Earnings of $0.44 Per Share 32Health News:Tyco International Reports Fourth Quarter Earnings From Continuing Operations Before Special Items of $0.61 Per Share and GAAP Earnings of $0.44 Per Share 33Health News:Center for Autism and Related Disorders Study Finds Hyperbaric Oxygen Therapy Ineffective Treatment for Children with Autism 2Health News:'The Time is Now for Better Pain Care for Patients' - Physician Leaders from Across Medicine Conclude from a Closed-Door Pain Summit 2Health News:'The Time is Now for Better Pain Care for Patients' - Physician Leaders from Across Medicine Conclude from a Closed-Door Pain Summit 3
...at exercise could benefit both the young and the o...n that exercise not only helps the elderly in prot... function, thus reducing the risk of Upper Respira... and a frequent problem in the ambulatory setting....
...ich is a serious problem in people with cancer, AI...iver, lungs and heart. A recent study has found th...d in fruit flies, where it is involved in muscle d...ce. Mice that were genetically modified to lack th...
... Carolina in Chapel Hill that was published in the...suggests that two genes - C282Y and H63D, which ar...osis may also lead to an increased risk of develop...re matched with healthy controls. Researchers also...
...y in a hospital in Switzerland who investigated w...tory prostate cancer could be measured via changes...state cancer doubling time may be an auxiliary mar...efractory prostate cancer and bi-dimensionally mea...
...fts University in Boston has revealed that childre...ions displayed on television. They also use emotio...to make decisions. Donna Mumme, assistant pro...holder, a blue bumpy ball, and a yellow garden hos...
...otechnology outlines a new method developed by Mic...nes required for the production of industrial mole... in the company's ability to improve the propertie...mize a cell's metabolic potential to increase prod...
Other Medicine News:
(Date:11/10/2009)...IA, November 10 , ... of Excellence in Serving,Healthcare Needs of Pati...,Michigan and Ohio , Elsevier ( http://w...d,medical publishing and online solutions, today a...health.org ), the nation,s fourth largest Catholic...
(Date:11/10/2009)...0 Despite the global economic decl...such as Poland, the Czech Republic, Slovakia, Hung...ctive healthcare market. Both the pharmaceutical a...ped to their full potential, with healthcare expen...mportance of this market is attracting multination...
(Date:11/10/2009).... 10 /PRNewswire/ -- JumpStart Inc., the Northea...lerates the progress of high growth early-stage bu...t commitment of $250,000 in Checkpoint Surgical, L...OH medical device company is developing and commer...mulator. ,, (Logo: http://www.newscom.com/cg...
Breaking Medicine Technology:Trinity Health Selects Seven Elsevier Clinical Decision Support Solutions for its Multiple Facilities In Seven States 2Trinity Health Selects Seven Elsevier Clinical Decision Support Solutions for its Multiple Facilities In Seven States 3Trinity Health Selects Seven Elsevier Clinical Decision Support Solutions for its Multiple Facilities In Seven States 4Central and Eastern European Healthcare Markets Hold Strong Potential for Growth Despite the Economic Slowdown, Says Frost & Sullivan 2Central and Eastern European Healthcare Markets Hold Strong Potential for Growth Despite the Economic Slowdown, Says Frost & Sullivan 3JumpStart Invests in Checkpoint Surgical 2JumpStart Invests in Checkpoint Surgical 3APHL Chosen by PEPFAR to Develop Global Health Laboratory Systems 54384 1APHL Chosen by PEPFAR to Develop Global Health Laboratory Systems 54384 2Lifting weights reduces lymphedema symptoms following breast cancer surgery Penn research shows 54380 1Lifting weights reduces lymphedema symptoms following breast cancer surgery Penn research shows 54380 2Lifting weights reduces lymphedema symptoms following breast cancer surgery Penn research shows 54380 3Statement from the American College of Surgeons Regarding Recent Comments from President Obama 54376 1Statement from the American College of Surgeons Regarding Recent Comments from President Obama 54376 2
...ss.--(BUSINESS WIRE)--Mar 26, 2007 - CombinatoRx,...inary results of,a phase 2 clinical trial studying...olone and the antidepressant paroxetine),and 3mg p...hritis,(RA). This trial served two important purpo...g of prednisolone alone (a very low dose),in RA an...
...tudy in Seventy Type 2 Diabetes Patients -, MONT...nc.,(TSX:CJB) today announced positive prelimina...nical study for the treatment of Type 2,diabetes...n-4.,Results from the study demonstrated that PC...and, when administered once-weekly at each,of th...
Other Medicine Technology:CombinatoRx Provides Topline Results from Phase 2 RA Study with,CRx-139 and Very Low Dose Prednisolone 2CombinatoRx Provides Topline Results from Phase 2 RA Study with,CRx-139 and Very Low Dose Prednisolone 3CombinatoRx Provides Topline Results from Phase 2 RA Study with,CRx-139 and Very Low Dose Prednisolone 4CombinatoRx Provides Topline Results from Phase 2 RA Study with,CRx-139 and Very Low Dose Prednisolone 5CombinatoRx Provides Topline Results from Phase 2 RA Study with,CRx-139 and Very Low Dose Prednisolone 6PC-DAC:Exendin-4 Phase I/II Multiple-Dose Study Preliminary Results,Demonstrate Safety and Efficacy at Once-Weekly Dosing 2PC-DAC:Exendin-4 Phase I/II Multiple-Dose Study Preliminary Results,Demonstrate Safety and Efficacy at Once-Weekly Dosing 3PC-DAC:Exendin-4 Phase I/II Multiple-Dose Study Preliminary Results,Demonstrate Safety and Efficacy at Once-Weekly Dosing 4
ACCUTEST H. pylori Test (Whole Blood)
OraQuick Rapid HIV-1 Antibody Test
...ous Mononucleosis test is designed to detect the I...e blood. The QuickVue+ Infectious Mononucleosis as...ch give a greater sensitivity and specificity than...ythrocytes. QuickVue+ Infectious Mononucleosis is ...
...irst available point-of-care diagnostic test that ...nfluenza A and B. The test uses a unique substrate...ts viral replication by promoting the release of t...te is labeled with a chromagen. When influenza vir...
Medicine Products: